Inventor
MACDONALD DOUGLAS
US41 patents
⚠️ This page may combine multiple inventors who share the name “MACDONALD DOUGLAS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
31 patentsUS9550837B2Jan 24, 2017
Therapeutic uses of anti-PCSK9 antibodies
REGENERON PHARMA31 citations98
US8357371B2Jan 22, 2013
Methods for treating hypercholesterolemia using antibodies to PCSK9
REGENERON PHARMA89 citations97
US10023654B2Jul 17, 2018
Anti-PCSK9 antibodies
REGENERON PHARMA16 citations92
US9475875B2Oct 25, 2016
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA14 citations92
US8791244B2Jul 29, 2014
Anti-ErbB3 antibodies and uses thereof
REGENERON PHARMA12 citations92
US9447173B2Sep 20, 2016
Human antibodies to respiratory syncytial virus F protein and methods of use thereof
REGENERON PHARMA37 citations90
US10941210B2Mar 9, 2021
Anti-PCSK9 antibodies
REGENERON PHARMA6 citations84
US11142578B2Oct 12, 2021
Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof
REGENERON PHARMA6 citations83
US9827310B2Nov 28, 2017
Anti-ErbB3 antibodies and uses thereof
REGENERON PHARMA4 citations83
US9724411B2Aug 8, 2017
Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9
REGENERON PHARMA15 citations83
US9309326B2Apr 12, 2016
Readily isolated bispecific antibodies with native immunoglobulin format
REGENERON PHARMA5 citations83
US9284380B2Mar 15, 2016
Anti-ErbB3 antibodies and uses thereof
REGENERON PHARMA5 citations83
US10125188B2Nov 13, 2018
Human antibodies to respiratory syncytial virus F protein and methods of use thereof
REGENERON PHARMA6 citations80
US12269897B2Apr 8, 2025
Anti-PCSK9 antibodies
REGENERON PHARMA1 citations75
US10738124B2Aug 11, 2020
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA3 citations73
US11168111B2Nov 9, 2021
Readily isolated bispecific antibodies with native immunoglobulin format
REGENERON PHARMA3 citations72
US10632194B2Apr 28, 2020
Anti-ErbB3 antibodies and uses thereof
REGENERON PHARMA2 citations72
US9982013B2May 29, 2018
Readily isolated bispecific antibodies with native immunoglobulin format
REGENERON PHARMA3 citations72
US9273143B2Mar 1, 2016
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
REGENERON PHARMA6 citations72
US10806780B2Oct 20, 2020
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
REGENERON PHARMA4 citations70
US12577304B2Mar 17, 2026
Anti-CD3 antibodies with low binding affinity
REGENERON PHARMA0 citations62
US12545735B2Feb 10, 2026
Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
REGENERON PHARMA0 citations62
US12157758B2Dec 3, 2024
Readily isolated bispecific antibodies with native immunoglobulin format
REGENERON PHARMA0 citations62
US11771762B2Oct 3, 2023
Anti-ErbB3 antibodies and uses thereof
REGENERON PHARMA0 citations62
US11608380B2Mar 21, 2023
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA0 citations62
US10047160B2Aug 14, 2018
Anti-EGFRvIII antibodies and uses thereof
REGENERON PHARMA1 citations62
US12115216B2Oct 15, 2024
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
REGENERON PHARMA0 citations59
US11559576B2Jan 24, 2023
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
REGENERON PHARMA1 citations59
US9116159B2Aug 25, 2015
VEGF-A121 assay
REGENERON PHARMA2 citations57
US9751932B2Sep 5, 2017
Anti-big-endothelin-1 (big-ET-1) antibodies and uses thereof
REGENERON PHARMA0 citations50
US9459263B2Oct 4, 2016
VEGF-A121 assay
REGENERON PHARMA0 citations47